Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 7Completed 5Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Learning Disabilities 1Dyslexia 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lovastatin × Clear all
NCT02964884 2025-06-24

Interventions for Reading Disabilities in NF1

Vanderbilt University

Phase 2 Active not recruiting
120 enrolled
CNS

Dyslexia, Learning Disabilities, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡